Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 3
5(45.5%)
Phase 2
3(27.3%)
Phase 1
2(18.2%)
Early Phase 1
1(9.1%)
11Total
Phase 3(5)
Phase 2(3)
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07462702Early Phase 1Not Yet Recruiting

Topical Minocycline for CARP

Role: collaborator

NCT02129660Phase 2Completed

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Role: lead

NCT05296629Phase 3Completed

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Role: lead

NCT05343455Phase 3Completed

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

Role: lead

NCT05597462Phase 1Completed

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Role: lead

NCT05452785Phase 1Completed

A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects

Role: lead

NCT02530281Phase 3Completed

Study of Glycopyrronium in Axillary Hyperhydrosis

Role: lead

NCT02530294Phase 3Completed

Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Role: lead

NCT02553798Phase 3Completed

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Role: lead

NCT02016885Phase 2Completed

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Role: lead

NCT03880266Phase 2Completed

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Role: lead

All 11 trials loaded